Rheumatoid Arthritis Drug Falls Short in Treating COVID-19

Credit: CDC/ Alissa Eckert, MS; Dan Higgins, MAMS

Roche rheumatoid arthritis drug fails to help COVID-19 patients in Italian study

by Emilio ParodiCarl O’Donnell

Despite the setback, the Swiss drugmaker said that it is pressing ahead with testing Actemra in another trial against COVID-19, the disease caused by the new coronavirus.

Actemra did not reduce severe respiratory symptoms, intensive care visits, or death any better than standard treatments, the Italian Medicines Agency (Aifa), Italy’s drugs regulator which authorized the study, said in a statement on Wednesday.

The trial, which enrolled 126 patients, about a third of the intended number, was stopped early after an interim analysis raised doubts about the anti-inflammatory medicine’s effectiveness.

“Although not effective in all patients with COVID-19 pneumonia, it is possible that selected subgroups of patients may have a better response,” Aifa said.

Read More:

Due to the nature of independent content, VT cannot guarantee content validity.
We ask you to Read Our Content Policy so a clear comprehension of VT's independent non-censored media is understood and given its proper place in the world of news, opinion and media.

All content is owned by author exclusively. Expressed opinions are NOT necessarily the views of VT, other authors, affiliates, advertisers, sponsors, partners or technicians. Some content may be satirical in nature. All images within are full responsibility of author and NOT VT.

About VT - Read Full Policy Notice - Comment Policy


  1. Mandoo:
    HCQ is really useless. We know the science and did the work. It was one of 40 drugs that might have controlled ACE 2. It didn’t. Pepcid works better. Dead horse, beaten twice. Then there’s the scam, Kusner was supposed to make billions on it instead and you need to pay fucking attention, it killed lots of people including many vets who were given it under very bad circumstances in understaffed VT facilities. HQC is a killer.

Comments are closed.